share_log

Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger With NorthView Acquisition Corp

Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger With NorthView Acquisition Corp

引領下一代個性化醫療的數字健康公司普羅蘇薩公司將通過與Northview收購公司合併成為一家上市公司
GlobeNewswire ·  2022/11/08 05:09

New York, New York, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa"), a digital health company that is pioneering the next generation of personalized medicine and NorthView Acquisition Corp. "NorthView") (Nasdaq: NVAC), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the "Business Combination Agreement") on November 7, 2022 that will result in Profusa becoming a publicly listed company.

紐約,紐約,2022年11月7日(Global Newswire)--Prousa,Inc.(“Prousa”),一家引領下一代個性化醫療和Northview收購公司的數字健康公司。上市特殊目的收購公司諾斯維尤)(納斯達克股票代碼:NVAC)今天宣佈,雙方已於2022年11月7日簽署了一項最終的業務合併協議(“業務合併協議”),普羅富薩將成為一家上市公司。

Upon closing of the transaction, NorthView will be renamed "Profusa Inc." (the "Combined Company").

交易完成後,Northview將更名為“Prousa Inc.”。(“合併公司”)。

Profusa is based in Emeryville, CA and is a digital health company that is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors. Profusa's technology addresses the human body's response to the presence of foreign material, enabling long-term monitoring of various biochemical parameters in real-time, with months of functionality, at a fraction of the cost of current solutions. Profusa's novel approach, that has been in development for approximately nine years, is intended to be the foundational platform of bioengineered sensors supporting real time biochemical monitoring, enabling a real-time stream of data for a wide-ranging set of applications, including wound care and continuous glucose monitoring for diabetes management. Profusa's technology enables continuous transmission of wireless and cloud based actionable medical-grade data for personal, professional and medical use.

普羅夫薩總部設在加利福尼亞州埃默裏維爾,是一家通過開發新型組織集成生物傳感器來引領下一代個性化醫療的數字健康公司。普羅富薩的技術解決了人體對外來物質存在的反應,實現了對各種生化參數的實時長期監測,具有數月的功能,成本僅為目前解決方案的一小部分。Prousa的新方法已經開發了大約九年,旨在成為支持實時生化監測的生物工程傳感器的基礎平臺,為一系列廣泛的應用實現實時數據流,包括傷口護理和糖尿病管理的連續血糖監測。Prousa的技術可持續傳輸基於無線和雲的可操作醫療級別數據,用於個人、專業和醫療用途。

Profusa's Chairman and CEO, Ben Hwang, PhD and the current management team will continue to lead the Combined Company.

普羅普薩的 主席 首席執行官、Ben Hwang、博士和目前的管理團隊將繼續領導合併後的公司。

Ben Hwang of Profusa noted, "We are excited to partner with NorthView to accelerate our growth and bring our solution to those in need, creating a true enabling technology that provides a data-driven, user-based, real-time health decision solution."

Prousa的Ben Hwang指出:“我們很高興能與Northview合作,加快我們的發展,並將我們的解決方案帶給有需要的人,創造一種真正的使能技術,提供數據驅動的、基於用户的實時健康決策解決方案。”

Profusa's mission is to make our body's chemistry easily accessible to improve health and wellness, becoming the leader in the development of real-time biosensors that provide unprecedented data-driven insights into our overall health status. Smaller than the width of a few hairs, each biosensor is a flexible hydrogel fiber of approximately 3 mm in length and less than half a millimeter wide, it is easily injected under the skin for ease of deployment and long-term functionality. The hydrogel fiber is linked to light-emitting fluorescent molecules that continuously signal in proportion to the concentration of a body chemical, such as oxygen, glucose, or other biomolecules of interest. Unlike conventional sensors, such as those found in other continuous glucose monitors, this novel approach allows the Profusa sensing platform to deliver accurate data, with months of functionality per injection, at a cost that enables broad user adoption.

普魯薩的使命是使我們身體的化學物質更容易獲得,以改善健康和健康,成為實時生物傳感器開發的領先者,這種傳感器可以為我們的整體健康狀況提供前所未有的數據驅動的洞察。每個生物傳感器的寬度小於幾根頭髮,是一種長度約為3毫米、寬度小於半毫米的柔性水凝膠纖維,它可以輕鬆地注射到皮膚下,便於部署和長期使用。水凝膠纖維與發光的熒光分子相連,這些熒光分子與體內化學物質的濃度成比例地持續發出信號,例如氧氣、葡萄糖或其他感興趣的生物分子。與傳統傳感器(如其他連續血糖監測儀中的傳感器)不同,這種新穎的方法允許普羅瓦傳感平臺提供準確的數據,每次注射具有數月的功能,成本使用户能夠廣泛採用。

Profusa's first product offering, currently  registered under CE Mark in the European Union, the Lumee™ Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee™ Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Profusa's second offering is in clinical development for continuous glucose monitoring (CGM). The global CGM market size is expected to grow from $6.13 billion in 2021 to $16.33 billion by 2030 at CAGR of 17.33% according to Strategic Market Research due principally to the rising incidence of diabetes, new product launches and government initiatives.

普羅維薩的第一個產品目前在歐盟以CE標誌註冊,即LuMee™氧氣平臺,旨在報告不同感興趣區域的可靠組織氧氣水平,包括急性和長期。這個路美™氧氣平臺專為監測受損組織有益的應用而設計,例如外周動脈疾病;不能正確癒合的慢性傷口(糖尿病潰瘍、壓瘡);以及重建手術。Prousa的第二個產品是用於持續血糖監測(CGM)的臨牀開發。根據Strategic Market Research的數據,全球CGM市場規模預計將從2021年的61.3億美元增長到2030年的163.3億美元,複合年增長率為17.33%,主要原因是糖尿病發病率上升、新產品推出和政府舉措。

Jack Stover, CEO of NorthViewcommented: "We believe our merger with Profusa represents a rare opportunity to partner with a management team and business that is highly sought after to be a public company with a true platform solution, globally focused and with technology validated via product approval and ready for launch. We are confident that this business combination will provide Profusa or the Combined Company with the financial resources to launch its commercial plans for its oxygen biosensor product, seek FDA approval for its continuous glucose monitoring product and continue to develop near term revenue opportunities to leverage its novel tissue integrated biosensor technology platform."  

北景首席執行官傑克·斯托弗, 我們相信,我們與Prousa的合併是一個難得的機會,可以與管理團隊和業務合作,成為一家備受追捧的上市公司,擁有真正的平臺解決方案,專注於全球,擁有經過產品批准並準備推出的技術。我們相信,這一業務合併將為Prousa或合併後的公司提供財務資源,以啟動其氧氣生物傳感器產品的商業計劃,尋求FDA對其連續血糖監測產品的批准,並繼續發展短期收入機會,以利用其新型組織集成生物傳感器技術平臺。

Transaction Overview

交易概覽

The pro forma equity valuation of the Combined Company is expected to be approximately $264 million assuming 80% redemptions or approximately $416 million assuming no redemptions. Estimated cash proceeds to the Combined Company from the transaction are expected to consist of NorthView's approximately $39 million of cash in trust assuming 80% redemptions or approximately $193 million assuming no redemptions.

假設80%的贖回,合併後公司的預計股本估值約為2.64億美元,或假設沒有贖回,約為4.16億美元。合併後公司從交易中獲得的預計現金收益預計將包括Northview公司約3900萬美元的信託現金,假設贖回80%,或假設沒有贖回,約1.93億美元。

Upon the closing of the transaction, and assuming 80% of NorthView's public stockholders elect to redeem their shares of common stock and no additional shares of common stock are issued upon the closing of the transaction, it is anticipated that NorthView's public stockholders would retain an ownership interest of approximately 21.6% in the Combined Company, the sponsors, officers, directors and other holders of NorthView founder shares will retain an ownership interest of approximately 19.7% of the Combined Company, and the Profusa stockholders will own approximately 58.7% of the Combined Company.

交易完成後,假設Northview的公眾股東中有80%選擇贖回他們的普通股,並且交易完成時沒有發行額外的普通股,預計Northview的公眾股東將保留合併後公司約21.6%的所有權權益,Northview方正股份的發起人、高級管理人員、董事和其他股東將保留合併後公司約19.7%的所有權權益,普羅富薩股東將擁有合併後公司約58.7%的所有權權益。

Alternatively, assuming no redemptions by NorthView's public stockholders and no additional shares of common stock are issued upon the closing of the transaction, it is anticipated that NorthView's public stockholders would retain an ownership interest of approximately 50.2% in the Combined Company, the sponsors, officers, directors and other holders of NorthView founder shares will retain an ownership interest of approximately 12.5% of the Combined Company, and the Profusa stockholders will own approximately 37.3% of the Combined Company.

或者,假設交易完成時Northview的公眾股東沒有贖回,也沒有發行額外的普通股,預計Northview的公眾股東將保留合併後公司約50.2%的所有權權益,Northview方正股份的發起人、高級管理人員、董事和其他股東將保留合併後公司約12.5%的所有權權益,而普羅富薩股東將擁有合併後公司約37.3%的所有權權益。

The board of directors of each of NorthView and Profusa has approved the transaction. NorthView, Profusa and certain stockholders of Profusa (the "Key Profusa Stockholders") have entered into support agreements pursuant to which such Key Profusa Stockholders agreed to, among other things, within five (5) business days after the proxy statement/prospectus relating to the approval by NorthView shareholders of the transaction is declared effective by the Securities and Exchange Commission and delivered or otherwise made available to NorthView shareholders, execute and deliver a written consent with respect to the outstanding shares of Profusa common stock and preferred stock held by the Key Profusa Stockholders adopting the Business Combiantion Agreement and related transactions. The shares of Profusa common stock and preferred stock that are owned by the Key Profusa Stockholders and subject to such support agreements represent a majority of the outstanding voting power of Profusa common stock and preferred stock (on an as converted basis). The transaction will require the approval of the stockholders of Profusa and NorthView and is subject to other customary closing conditions including the receipt of certain regulatory approvals.

Northview和Prousa的董事會都已經批准了這筆交易。Northview、PROFUSA及PROUSA的若干股東(“主要PROUSA股東”)已訂立支持協議,據此,該等主要PROUSA股東同意(其中包括)在有關Northview股東批准交易的委託書/招股章程被證券及交易委員會宣佈生效並交付或以其他方式提供予Northview股東後五(5)個營業日內,就主要PROUSA股東持有的已發行股份籤立及交付一份書面同意書,以供採納業務合併協議及相關交易。主要股東持有的普魯薩普通股和優先股的股份代表普魯薩普通股和優先股(按折算基礎)的大部分投票權,並受該等支持協議的約束。這筆交易將需要得到普羅富薩和Northview股東的批准,並取決於其他慣常的成交條件,包括獲得某些監管批准。

Additional information about the proposed transaction, including a copy of the business combination, will be provided in a Current Report on Form 8-K to be filed by NorthView with the SEC and available at www.sec.gov.

有關擬議中的交易的更多信息,包括業務合併的副本,將在Northview向美國證券交易委員會提交的最新8-K表格中提供,可在www.sec.gov上查閲。

Advisors

顧問

I-Bankers Securities Inc. and Dawson James Securities, Inc. acted as financial advisors to NorthView. H.C. Wainwright & Co. acted as financial advisor to Profusa. ArentFox Schiff LLP acted as legal advisor to NorthView and Sidley Austin LLP acted as legal advisor to Profusa.

I-Bankers證券公司和道森·詹姆斯證券公司擔任Northview的財務顧問。H.C.Wainwright&Co.擔任普羅富薩的財務顧問。ArentFox Schiff LLP擔任Northview的法律顧問,Sidley Austin LLP擔任Prousa的法律顧問。

About Profusa

關於普魯薩

Profusa, a Delaware corporation, is a digital health company that is pioneering the next generation of personalized medicine as a leading developer of novel tissue integrated biosensors.

Prousa是一家位於特拉華州的數字健康公司,作為新型組織集成生物傳感器的領先開發商,該公司正在開創下一代個性化醫學。

About NorthView

關於Northview

NorthView Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. NorthView was incorporated under the laws of the State of Delaware on December 22, 2021.

Northview Acquisition Corp.是一家空白支票公司,其成立的目的是與一個或多個企業進行合併、資本換股、資產收購、股票購買、重組或類似的業務合併。Northview於2021年12月22日根據特拉華州的法律成立。

Forward-Looking Statements

前瞻性陳述

This press release contains forward-looking statements within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and section 21E of the U.S. Securities Exchange Act of 1934 ("Exchange Act") that are based on beliefs and assumptions and on information currently available to NorthView and Profusa. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "target," "seek" or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including projections of market opportunity and market share, the capability of Profusa's business plans including its plans to expand, the sources and uses of cash from the proposed transaction, the anticipated enterprise value of the combined company following the consummation of the proposed transaction, any benefits of Profusa's partnerships, strategies or plans as they relate to the proposed transaction, anticipated benefits of the proposed transaction and expectations related to the terms and timing of the proposed transaction are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each of NorthView and Profusa believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of NorthView and Profusa caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the proposed transaction, which is expected to be filed by NorthView with the SEC and other documents filed by NorthView or Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Neither NorthView nor Profusa can assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to complete the business combination due to the failure to obtain approval from NorthView's stockholders or satisfy other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of the business combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by NorthView's public stockholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under the heading "Risk Factors" in the final prospectus for NorthView's initial public offering filed with the SEC on December 22, 2021 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional risks that neither NorthView or Profusa presently know or that NorthView and Profusa currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by NorthView, Profusa, their respective directors, officers or employees or any other person that NorthView and Profusa will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent the views of NorthView and Profusa as of the date of this communication. Subsequent events and developments may cause those views to change. However, while NorthView and Profusa may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of NorthView or Profusa as of any date subsequent to the date of this communication.

本新聞稿包含1933年修訂的美國證券法(“證券法”)第27A節和1934年美國證券交易法(“交易法”)第21E節所指的前瞻性陳述,這些陳述是基於信念和假設以及Northview和Prousa目前掌握的信息。在某些情況下,您可以通過以下詞語來識別前瞻性陳述:“可能”、“將”、“可能”、“將”、“應該”、“預期”、“打算”、“計劃”、“預期”、“相信”、“估計”、“預測”、“項目”、“潛在”、“繼續”、“正在進行”、“目標”、“尋求”或這些詞語的否定或複數,或其他類似的預測或表明未來事件或前景的表述,儘管並非所有前瞻性陳述都包含這些詞語。任何提及未來事件或情況的預期、預測或其他特徵的表述,包括對市場機會和市場份額的預測、普羅富薩的業務計劃(包括其擴張計劃)的能力、擬議交易的現金來源和用途、合併後公司在擬議交易完成後的預期企業價值、普羅富薩的合作伙伴關係、戰略或計劃與擬議交易相關的任何好處、擬議交易的預期效益以及與擬議交易的條款和時機相關的預期,均屬前瞻性陳述。這些表述涉及風險、不確定因素和其他因素,可能導致實際結果、活動水平、業績或成就與這些前瞻性表述明示或暗示的內容大不相同。儘管諾斯維尤和普羅富薩各自認為,本新聞稿中包含的每一項前瞻性陳述都有合理的基礎, Northview和Profusa都提醒您,這些陳述是基於目前已知的事實和因素以及對未來的預測的組合,這些內在地是不確定的。此外,與擬議中的交易有關的S-4表格委託書/招股説明書中將描述風險和不確定因素,預計Northview將向美國證券交易委員會提交該交易,以及Northview或Provusa不時向美國證券交易委員會提交的其他文件。這些文件可能會確定和處理其他重要的風險和不確定因素,這些風險和不確定因素可能導致實際事件和結果與前瞻性陳述中包含的內容大不相同。Northview和普羅富薩都不能向您保證,本次通信中的前瞻性陳述將被證明是準確的。這些前瞻性陳述會受到大量風險和不確定性的影響,包括但不限於由於未能獲得Northview股東的批准或未能滿足業務合併協議中的其他成交條件而導致完成業務合併的能力、可能導致終止業務合併協議的任何事件的發生、確認業務合併的預期收益的能力、Northview公眾股東提出的贖回請求的金額、與交易相關的成本、全球新冠肺炎疫情的影響、由於交易的宣佈和完成而擾亂當前計劃和運營的風險,任何潛在訴訟、政府或監管程序的結果,以及其他風險和不確定性,包括將在12月22日提交給美國證券交易委員會的Northview首次公開募股的最終招股説明書中“風險因素”項下包括的風險和不確定性, 2021年,以及在隨後的10-Q表格季度報告和其他提交給美國證券交易委員會的文件中。可能存在Northview和Prousa目前都不知道的或者Northview和Prousa目前認為不重要的其他風險,這些風險也可能導致實際結果與前瞻性陳述中包含的結果不同。鑑於這些前瞻性陳述中存在的重大不確定性,您不應將這些陳述視為Northview、Profusa、其各自的董事、高級管理人員或員工或任何其他人關於Northview和Prousa將在任何特定時間框架內實現其目標和計劃的陳述或保證。本新聞稿中的前瞻性陳述代表了Northview公司和普羅富薩公司截至通信之日的觀點。隨後發生的事件和事態發展可能會導致這些觀點發生變化。然而,儘管Northview和普羅富薩未來可能會更新這些前瞻性陳述,但目前沒有這樣做的打算,除非適用法律要求這樣做。因此,您不應依賴這些前瞻性陳述,因為它們代表Northview或Profusa在本通訊日期之後的任何日期的觀點。

No Offer or Solicitation

沒有要約或懇求

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of NorthView or Profusa, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

本新聞稿不是關於任何證券或關於潛在交易的代理聲明或委託、同意或授權,也不構成出售或邀請購買Northview或Profusa的任何證券的要約,也不會在任何州或司法管轄區出售任何此類證券,在任何州或司法管轄區,在根據該州或司法管轄區的證券法註冊或獲得資格之前,此類要約、招攬或銷售將是非法的。除非招股説明書符合《證券法》的要求,否則不得提出證券要約。

Important Additional Information Regarding the Transaction Will Be Filed With the SEC

有關這筆交易的重要補充信息將提交給美國證券交易委員會

In connection with the proposed business combination, NorthView intends to file with the SEC a registration statement on Form S-4 containing a preliminary proxy statement and a preliminary prospectus of NorthView, and after the registration statement is declared effective, NorthView will mail a definitive proxy statement/prospectus relating to the proposed business combination to its stockholders and Profusa's shareholders. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. NorthView's stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about Profusa, NorthView and the proposed business combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders of NorthView as of a record date to be established for voting on the proposed business combination. Such stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request tofredknechtel@northviewac.com,, Attention: Fred Knechtel.

關於擬議的業務合併,Northview打算向美國證券交易委員會提交一份S-4表格的註冊説明書,其中包含一份初步的委託書和Northview的初步招股説明書,在註冊説明書宣佈生效後,Northview將向其股東和普羅富薩的股東郵寄與擬議的業務合併有關的最終委託書/招股説明書。本新聞稿不包含有關擬議業務合併的所有應考慮的信息,也不打算構成與該業務合併有關的任何投資決定或任何其他決定的基礎。建議Northview的股東和其他感興趣的人士閲讀初步委託書/招股説明書及其修正案,以及與擬議的業務合併有關的最終委託書/招股説明書和其他文件,因為這些材料將包含有關普魯薩、Northview和擬議的業務合併的重要信息。一旦最終委託書/招股説明書和其他相關材料可用,將郵寄給Northview的股東,以確定對建議的業務合併進行投票的記錄日期。這些股東還將能夠免費獲得提交給美國證券交易委員會的初步委託書/招股説明書、最終委託書/招股説明書和其他文件的副本,一旦可以獲得,可在美國證券交易委員會的網站www.sec.gov上獲得,或通過發送電子郵件至fredknechtel@northviewac.com,

Participants in the Solicitation

徵集活動的參與者

NorthView and Profusa and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of NorthView's stockholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of NorthView's stockholders in connection with the proposed business combination will be set forth in NorthView's registration statement on Form S-4, including a proxy statement/prospectus, when it is filed with the SEC.

根據美國證券交易委員會規則,Northview和Prousa及其各自的董事、高管、其他管理層成員和員工可能被視為參與了與擬議交易相關的Northview股東委託書的徵集。根據美國證券交易委員會規則,哪些人可能被視為與擬議的業務合併相關的Northview股東招標的參與者的信息,將在Northview向美國證券交易委員會提交的S-4表格註冊聲明中列出,包括委託書/招股説明書。

Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of NorthView's directors and officers in NorthView's filings with the SEC and such information will also be in the Registration Statement to be filed with the SEC by NorthView, which will include the proxy statement / prospectus of NorthView for the proposed transaction.

投資者和證券持有人可以在Northview提交給美國證券交易委員會的文件中獲得有關Northview董事和高級管理人員在擬議交易中的姓名和權益的更詳細信息,這些信息也將出現在Northview提交給美國證券交易委員會的註冊聲明中,其中將包括Northview針對建議交易的委託書/招股説明書。

For investor and media inquiries, please contact:

投資者和媒體查詢,請聯繫:

Fred Knechtel, CFO of NorthView: fredknechtel@northviewac.com
Sandeep Yadav, CFO of Profusa: Sandeep.yadav@profusa.com

Northview首席財務官弗雷德·克內赫特爾:郵箱:fredknechtel@northviewac.com
普魯薩首席財務官桑迪普·亞達夫電子郵件:sandeep.yadav@Profusa.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論